- Home
- TOPS vs GBIO Comparison
TOPS vs GBIO Comparison
Compare TOPS & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- GBIO
- Stock Information
- Founded
- TOPS 2000
- GBIO 2016
- Country
- TOPS Greece
- GBIO United States
- Employees
- TOPS N/A
- GBIO N/A
- Industry
- TOPS Marine Transportation
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- GBIO Health Care
- Exchange
- TOPS Nasdaq
- GBIO Nasdaq
- Market Cap
- TOPS 27.4M
- GBIO 29.2M
- IPO Year
- TOPS 2004
- GBIO 2020
- Fundamental
- Price
- TOPS $5.90
- GBIO $0.35
- Analyst Decision
- TOPS
- GBIO Strong Buy
- Analyst Count
- TOPS 0
- GBIO 4
- Target Price
- TOPS N/A
- GBIO $7.33
- AVG Volume (30 Days)
- TOPS 141.9K
- GBIO 1.1M
- Earning Date
- TOPS 08-08-2025
- GBIO 08-06-2025
- Dividend Yield
- TOPS N/A
- GBIO N/A
- EPS Growth
- TOPS N/A
- GBIO N/A
- EPS
- TOPS 1.09
- GBIO N/A
- Revenue
- TOPS $86,127,000.00
- GBIO $24,556,000.00
- Revenue This Year
- TOPS $9.90
- GBIO N/A
- Revenue Next Year
- TOPS N/A
- GBIO N/A
- P/E Ratio
- TOPS $5.41
- GBIO N/A
- Revenue Growth
- TOPS 3.83
- GBIO 146.47
- 52 Week Low
- TOPS $5.00
- GBIO $0.30
- 52 Week High
- TOPS $11.47
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- TOPS 47.69
- GBIO 44.93
- Support Level
- TOPS $5.10
- GBIO $0.32
- Resistance Level
- TOPS $6.00
- GBIO $0.36
- Average True Range (ATR)
- TOPS 0.48
- GBIO 0.03
- MACD
- TOPS -0.06
- GBIO -0.00
- Stochastic Oscillator
- TOPS 40.81
- GBIO 35.27
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.